Todd Asset Management LLC Makes New Investment in DaVita Inc. $DVA

Todd Asset Management LLC acquired a new position in DaVita Inc. (NYSE:DVA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 164,387 shares of the company’s stock, valued at approximately $21,842,000. Todd Asset Management LLC owned approximately 0.23% of DaVita at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Man Group plc grew its position in DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock valued at $40,713,000 after acquiring an additional 269,081 shares during the last quarter. Norges Bank bought a new position in shares of DaVita during the 2nd quarter valued at $32,986,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in DaVita in the 2nd quarter worth $21,554,000. Arrowstreet Capital Limited Partnership lifted its stake in DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock worth $37,619,000 after purchasing an additional 150,318 shares during the last quarter. Finally, Rakuten Investment Management Inc. bought a new position in shares of DaVita during the third quarter valued at about $19,875,000. Institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DVA. Barclays boosted their target price on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Truist Financial set a $158.00 target price on shares of DaVita in a report on Thursday, February 5th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Finally, UBS Group raised their price target on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $160.50.

DaVita Trading Down 0.6%

NYSE:DVA opened at $149.12 on Monday. The company has a 50-day moving average price of $117.71 and a 200-day moving average price of $124.74. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $159.27. The stock has a market cap of $9.96 billion, a price-to-earnings ratio of 15.05, a P/E/G ratio of 0.52 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter in the previous year, the company earned $2.24 earnings per share. DaVita’s quarterly revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.